Stryker Corp
NYSE:SYK

Watchlist Manager
Stryker Corp Logo
Stryker Corp
NYSE:SYK
Watchlist
Price: 364.02 USD -0.09% Market Closed
Market Cap: 139.2B USD

Stryker Corp
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Stryker Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Stryker Corp
NYSE:SYK
Cash & Cash Equivalents
$3.3B
CAGR 3-Years
32%
CAGR 5-Years
-14%
CAGR 10-Years
0%
Becton Dickinson and Co
NYSE:BDX
Cash & Cash Equivalents
$641m
CAGR 3-Years
-14%
CAGR 5-Years
-26%
CAGR 10-Years
-8%
Boston Scientific Corp
NYSE:BSX
Cash & Cash Equivalents
$1.3B
CAGR 3-Years
56%
CAGR 5-Years
-9%
CAGR 10-Years
14%
Abbott Laboratories
NYSE:ABT
Cash & Cash Equivalents
$7.5B
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
9%
IDEXX Laboratories Inc
NASDAQ:IDXX
Cash & Cash Equivalents
$208.2m
CAGR 3-Years
28%
CAGR 5-Years
3%
CAGR 10-Years
4%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash & Cash Equivalents
$8.4B
CAGR 3-Years
76%
CAGR 5-Years
44%
CAGR 10-Years
26%
No Stocks Found

Stryker Corp
Glance View

Stryker Corporation, a pioneering force in the medical technology industry, traces its roots back to the innovative spirit of Dr. Homer Stryker, an orthopedic surgeon whose dissatisfaction with existing medical equipment spurred him to improve them. Founded in 1941, the company initially focused on new medical devices that addressed specific problems faced by healthcare practitioners. Over the decades, Stryker has evolved into a diversified powerhouse with a portfolio that spans a wide range of products, including joint replacements, surgical equipment, neurotechnology, and spine care solutions. This evolution came through strategic acquisitions and relentless innovation, allowing Stryker to meet the ever-increasing demands of a dynamic healthcare landscape. The company's business model thrives at the intersection of technology and healthcare. With their cutting-edge research and development capabilities, Stryker consistently pushes the envelope in creating sophisticated products that enhance patient outcomes. Revenue streams are predominantly generated from the sale of medical and surgical equipment as well as a myriad of implantable surgical devices used in orthopedic procedures. Stryker’s instruments and solutions are staples in hospitals and clinics worldwide, driven by their commitment to quality and efficacy. Additionally, the company's astute investments in advanced robotics and digital health technologies have positioned it well within the burgeoning field of precision medicine, providing lucrative opportunities to deepen its market entrenchment and expand its competitive edge.

SYK Intrinsic Value
324.92 USD
Overvaluation 11%
Intrinsic Value
Price

See Also

What is Stryker Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.3B USD

Based on the financial report for Sep 30, 2025, Stryker Corp's Cash & Cash Equivalents amounts to 3.3B USD.

What is Stryker Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
0%

Over the last year, the Cash & Cash Equivalents growth was -15%. The average annual Cash & Cash Equivalents growth rates for Stryker Corp have been 32% over the past three years , -14% over the past five years .

Back to Top